Evidence map›Paper›PMID 39967679›Full record

ArticlePNAS nexus2025

Trisomic rescue via allele-specific multiple chromosome cleavage using CRISPR-Cas9 in trisomy 21 cells.

Ryotaro Hashizume, Sachiko Wakita, Hirofumi Sawada, Shin-Ichiro Takebayashi, Yasuji Kitabatake, Yoshitaka Miyagawa, Yoshifumi S Hirokawa, Hiroshi Imai, Hiroki Kurahashi

Abstract read
In one paragraph

Article in PNAS nexus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ryotaro HashizumeDepartment of Pathology and Matrix Biology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan.ORCID https://orcid.org/0000-0002-9237-029X
Sachiko WakitaDepartment of Pathology and Matrix Biology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan.
Hirofumi SawadaDepartment of Pediatrics, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan.ORCID https://orcid.org/0000-0001-8069-5751
Shin-Ichiro TakebayashiLaboratory of Molecular and Cellular Biology, Graduate School of Bioresources, Mie University, Tsu, Mie 514-8507, Japan.ORCID https://orcid.org/0000-0002-1968-9800
Yasuji KitabatakeDepartment of Pediatrics, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.ORCID https://orcid.org/0000-0002-2907-9512
Yoshitaka MiyagawaDepartment of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo 113-8602, Japan.ORCID https://orcid.org/0000-0003-2629-7503
Yoshifumi S HirokawaDepartment of Oncologic Pathology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan.
Hiroshi ImaiDepartment of Genomic Medicine, Mie University Hospital, Tsu, Mie 514-8507, Japan.ORCID https://orcid.org/0000-0002-7321-1533
Hiroki KurahashiDivision of Molecular Genetics, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake 470-1192, Japan.ORCID https://orcid.org/0000-0002-5690-5218

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human trisomy 21, responsible for Down syndrome, is the most prevalent genetic cause of cognitive impairment and remains a key focus for prenatal and preimplantation diagnosis. However, research directed toward eliminating supernumerary chromosomes from trisomic cells is limited. The present study demonstrates that allele-specific multiple chromosome cleavage by clustered regularly interspaced palindromic repeats Cas9 can achieve trisomy rescue by eliminating the target chromosome from human trisomy 21 induced pluripotent stem cells and fibroblasts. Unlike previously reported allele-nonspecific strategies, we have developed a comprehensive allele-specific (AS) Cas9 target sequence extraction method that efficiently removes the target chromosome. The temporary knockdown of DNA damage response genes increases the chromosome loss rate, while chromosomal rescue reversibly restores gene signatures and ameliorates cellular phenotypes. Additionally, this strategy proves effective in differentiated, nondividing cells. We anticipate that an AS approach will lay the groundwork for more sophisticated medical interventions targeting trisomy 21.

Indexed as

allele specificitychromosome cutchromosome lossCRISPR/CasDown syndromehuman trisomy 21

Identifiers

PMID39967679
PMCPMC11832276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.